Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.

Molecular biology reports - 1 Dec 2020

Jazireian Parham, Sasani Soheila Talesh, Assarzadegan Farhad, Azimian Mojtaba

Abstract excerpt

Multiple sclerosis (MS) is an autoimmune-type inflammatory disorder in human central nervous system. Recombinant interferon beta (IFN-β) decreases the number of relapses and postpones disability progression in MS. However, up to 50% of patients treated with interferon beta continue experiencing relapses and/or worsening disability. Single nucleotide polymorphisms in different genes have been known to show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunologic Factors
Share to Interferon-beta

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Pharmacogenetics

Share to Polymorphism, Restriction Fragment Length

Share to Receptor Activator of Nuclear Factor-kappa B

Share to Receptors, AMPA

Share to Recombinant Proteins

Source

Identifiers

PMID: 33269432
DOI: 10.1007/s11033-020-06026-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.PMID 33269432Read ↗

Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.Semantic proximity Read ↗

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.Semantic proximity Read ↗

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.Semantic proximity Read ↗

The efficacy of interferon-beta therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker.Semantic proximity Read ↗

Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple SclerosisSemantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.Semantic proximity Read ↗

TRAIL gene expression analysis in multiple sclerosis patients.Semantic proximity Read ↗

Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis.Semantic proximity Read ↗

Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.Semantic proximity Read ↗

CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients.Semantic proximity Read ↗

Polymorphisms in proinflammatory cytokines genes and susceptibility to Multiple Sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.